(Yicai Global) April 13 -- Guangdong province-based Hybribio Biotech's Covid-19 nucleic acid test has been given the green light by Brazil's national health bureau, paving the way for sales in the most populous South American country. 

The product is suitable for large-scale screening, the biotech firm said in a statement yesterday. The diagnostic tool received the European Union's CE marking in early March. 

Hybribio's shares [SHE:300639] climbed 3.8 percent to CNY30.85 (USD4.40) in the afternoon.

Editor: Emmi Laine